Celgene opens European R&D hub for translational science

Celgene has launched Celgene Institute of Translational Research Europe (CITRE), a European hub for

Celegene claimed that CITRE would bring together key parties from government, industry and academia. The collaboration's main objective is to minimise the gap between basic scientific research and clinical results, so that patients benefit sooner from laboratory discoveries.

Celegene said that the centre will be dedicated to therapeutic innovation via translational research: the linking of basic scientific discoveries in the laboratory with clinical advances.

Additionally, CITRE will focus on several research areas, including cell signalling, cellular therapies, tumour biobanking, epigenetics and bioinformatics. and will comprise five facilities: cell cultures, citometry, electronic microscopy, genomics and proteomics.

Sol Barer, chairman of the board and chief administrative officer of Celgene, said: "CITRE represents a new model for research in Europe, based on qualities that are fundamental to success: collaboration, communication and progress. This new research paradigm will expedite the discovery of innovative approaches in cellular therapies for patients with otherwise limited options who are in need of new solutions."

Thomas Daniel, president of Celgene Global Research, said: "CITRE is the first Celgene centre outside the US exclusively dedicated to R&D. CITRE will be managed by Celgene Corporation, a leader in therapies that improve patients' lives worldwide, to ensure global alignment for the company's research."